The Shareholders Foundation announces that an investigation on behalf of investors, who currently hold shares of Allergan, Inc. (NYSE:AGN) shares, was initiated concerning whether certain officers and directors of Allgeran, Inc breached their fiduciary duties owed to NYSE:AGN stockholders.
Investors who purchased shares of Allergan, Inc. (NYSE:AGN) and currently hold any of those NYSE:AGN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain officers and directors of Allergan, Inc. breached their fiduciary duties owed to NYSE:AGN investors in connection with the proposed acquisition.
On April 22, 2014, Allergan, Inc. (NYSE: AGN) confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc.to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of the Company. Based on Valeant’s closing stock price on April 21, 2014, Allergan shareholders would have received consideration valued at approximately $152.88 per share.
On May 12, 2014, Allergan, Inc announced that its board of directors rejected the offer announced by Valeant Pharmaceuticals International, Inc. on April 22, 2014.
On May 28, 2014, Allergan, Inc confirmed that it has received a revised, unsolicited proposal from Valeant Pharmaceuticals International, Inc. to acquire all of the outstanding shares of Allergan, Inc for a combination of 0.83 of Valeant Pharmaceuticals International common shares,$58.30 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales. On May 30, 2014, Allergan, Inc.(NYSE: AGN) acknowledged that Valeant Pharmaceuticals International, Inc. and Pershing Square Capital Management, L.P. have made a second revised, unsolicited proposal to acquire all of the outstanding shares of Allergan, Inc for a combination of 0.83 of Valeant Pharmaceuticals International common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales. On June 23, 2014 Allergan, Inc announced that its board of directors rejected the offer made by Valeant Pharmaceuticals International, Inc. and Pershing Square Capital Management, L.P. on May 30, 2014.
On October 27, 2014, Valeant Pharmaceuticals International, Inc delivered a letter to the board of directors of Allergan, Inc. Among other things, Valeant Pharmaceuticals International, Inc stated that it is prepared to improve its offer and provide value to Allergan shareholders of at least $200 a share.
The investigation concerns whether the Allergan Board of Directors undertakes an adequate sales process, adequately shops the company before entering into any transaction, maximizes shareholder value by negotiating the best price, and most importantly acts in the shareholders’ best interests in connection with the proposed sale.
Allergan, Inc. reported that its annual Total Revenue rose from over $4.491 billion in 2010 to over $6.3 billion in 2013 and that its respective Net Income increased from $0.60 million to $985.10 million. Shares of Allergan, Inc. (NYSE:AGN) grew from $43.75 per share in May 2009 to as high as $131.43 per share in March 2014 and rose to as high as $190.50 per share since the offers by Valeant Pharmaceuticals International.
On October 31, 2014, Allergan, Inc. (NYSE:AGN) shares closed at $190.06 per share.
Those who are current investors in Allergan, Inc. shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com